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stratakc@mail.nih.govAbstractX-linked acrogigantism (X-LAG) is a new syndrome of pituitary gigantism, caused by
microduplications on chromosome Xq26.3, encompassing the gene GPR101, which is highly
upregulated in pituitary tumors. We conducted this study to explore the clinical, radiological, and
hormonal phenotype and responses to therapy in patients with X-LAG syndrome. The study
included 18 patients (13 sporadic) with X-LAG and microduplication of chromosome Xq26.3.
All sporadic cases had unique duplications and the inheritance pattern in two families was
dominant, with all Xq26.3 duplication carriers being affected. Patients began to grow rapidly as
early as 2–3 months of age (median 12 months). At diagnosis (median delay 27 months), patients
had a median height and weight standard deviation scores (SDS) ofOC3.9 SDS. Apart from the
increased overall body size, the children had acromegalic symptoms including acral enlargement
and facial coarsening. More than a third of cases had increased appetite. Patients had marked
hypersecretion of GH/IGF1 and usually prolactin, due to a pituitary macroadenoma or
hyperplasia. Primary neurosurgical control was achieved with extensive anterior pituitary
resection, but postoperative hypopituitarism was frequent. Control with somatostatin analogs
was not readily achieved despite moderate to high levels of expression of somatostatin receptor
subtype-2 in tumor tissue. Postoperative use of adjuvant pegvisomant resulted in control of IGF1
inallfivecaseswhere itwasemployed.X-LAGisanewinfant-onsetgigantismsyndromethathasa









(2015) 22, 353–367IntroductionPituitary gigantism is a rare condition associated with
hypersecretion of growth hormone (GH) by a pituitary
tumor or hyperplasia before the complete fusion of growth
plates, leading to pathological tall stature (Eugster &
Pescovitz 1999, Davies & Cheetham 2014). Chronic GH
hypersecretion leads to the development of signs and
symptoms of acromegaly, which continue to develop after
the attainment of final height. Although it is a well-
recognized condition among the medical and general
populations (de Herder 2015), the genetic etiology of
pituitary gigantism remained poorly understood until
recently. Pituitary gigantism can occur as a feature of a
number of monogenic disorders. Approximately one-third
of acromegaly patients with germline mutations in the arylhydrocarbon receptor interacting protein (AIP) gene have
gigantism (Beckers et al. 2013), and additional etiologies
include mosaicism for GNAS mutations in McCune–
Albright syndrome (MAS), germline PRKAR1A mutations
in Carney complex, or rarely MEN1 mutations (Stratakis
et al. 2000, Salenave et al. 2014, Salpea & Stratakis 2014).
We have recently described a new disorder of X-linked
acrogigantism (X-LAG) that is due to microduplications of
chromosome Xq26.3 (MIM#300942) that involve the gene
for the orphan G protein-coupled receptor (GPCR),
GPR101, which is highly upregulated in pituitary tumors
from affected patients (Trivellin et al. 2014). X-LAG is
a distinctive clinical entity that is characterized by
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22 :3 355AUTHOR COof life in previously normal infants. The overgrowth iscaused by GH hypersecretion from hyperplasia and/or a
pituitary macroadenoma. X-LAG can occur as a sporadic
condition or can present as familial isolated pituitary
adenomas (FIPAs) in acrogigantism kindreds. This newly
described condition is rare and the phenotype is incom-
pletely characterized, particularly in terms of clinical
responses to treatment. The aim of the current study was
to clinically characterize X-LAG in an expanded cohort of
18 affected patients.Methods
The study population consisted of 18 patients with X-LAG
syndrome, of whom five were familial and 13 were sporadic
(basic diagnostic/genetic data were presented on 13 cases in
Trivellin et al. (2014)). Patients underwent genetic diagnosis
(peripheral blood DNA) using clinical array comparative
genomic hybridization (aCGH) and research-based
high-definition array CGH. All tested patients had a
microduplication of chromosome Xq26.3. Breakpoint
analyses were performed using long-range PCR techniques.
Fluorescence in situ hybridization (FISH) studies using
Xq26.3 microduplication specific probes were also per-
formed on peripheral blood leukocytes from a subset of
patients as described previously (Trivellin et al. 2014).
During this study a comprehensive set of data on the
demographic, clinical, radiological, hormonal, patho-
logical, and therapeutic outcomes in the patient population
was collected under the following headings (individual
criteria are listed in Supplementary materials and methods,
see section on supplementary data given at the end of this
article): demographics and background parameters; birth
and family characteristics; growth disorder characteristics;
symptoms and hormone disturbances; pituitary imaging
characteristics; treatment; outcomes.Pathology
Staining of formalin-fixed paraffin-embedded (FFPE) tissue
samples of pituitary tumors for pituitary hormones (GH, PRL,
ACTH, FSH, LH, and TSH), and GH-releasing hormone
receptor (GHRHR) were performed as described previously
(Magri et al. 2010, Trivellin et al. 2014). Immunohistochem-
ical stains for somatostatin receptors (SSTRs) were performed
using an automated immunostainer (Ventana Medical
Systems, Tucson, AZ, USA) as reported previously (Lee et al.
2013). The SuperSentitive immunohistochemistry (IHC)
detection system from BioGenex (Fremon, CA, USA) was
used to visualize the antibody binding following thehttp://erc.endocrinology-journals.org q 2015 Society for Endocrinology
DOI: 10.1530/ERC-15-0038 Printed in Great BritainPY ONLYmanufacturer’s instructions. Sections were counterstainedwith Mayer’s Haemalum, dehydrated, and coverslips were
fitted. The primary antibodies directed against SSTR2 (clone
UMB-1 reacting with the SSTR2a isoform, dilution: 1:500),
SSTR3 (clone UMB-5, dilution: 1:750), and SSTR5 (clone
UMB-4, dilution: 1:75) were purchased from Abcam
(Cambridge, MA, USA). Sections of normal pancreas were
used as a positive control and included in each run. Sections
incubated without the primary antibody were included in
each batch as a negative control. Immunostains were
evaluated semiquantitatively by two individuals on acquired
images. An immunoreactive score (IRS) was recorded for each
section as reported (Lee et al. 2014). Briefly, the IRS was
generated on the basis of the intensity of the staining
(no staining, 0; mild, 1; moderate, 2; strong, 3) and the
percentage of cells showing membranous or cytoplasmic
expression (no positive cells, 0; !10% positive cells, 1;
10–50% positive cells, 2; 51–80% positive cells, 3; and
O80% positive cells, 4). The overall IRS was calculated as
(percentage of positive cells)!(intensity of staining). We
considered the staining as being negative for IRS 0 and 1,
weakly positive for IRS 2 and 3, moderately positive for IRS
4–8, and strongly positive for IRS O8. Immunostains for
anterior pituitary hormones, Ki67 (MIB1), and AIP were
performed as described (Jaffrain-Rea et al. 2009, Villa et al.
2011). Briefly, AIP/ARA9 antibody (Novus Biologicals,
Littleton, Colorado, USA) was used at a dilution of
1:2000 and processed using an automated protocol for
Benchmark Ventana.Statistical analysis
Data were collated and expressed as medians and ranges.
As the data were not normally distributed, comparisons of
data between subgroups by sex were performed using the
Mann–Whitney U test.Literature review
We conducted a comprehensive study of the literature on
gigantism from the extensive historical collection of one
of the authors (W W dH) that includes images, medical
information, family accounts, media reports, and other
items. These items formed the basis of a secondary search
of the medical literature in terms of original scientific
publications, books, and manuscripts dealing with gigant-
ism and acromegaly among children. Cases in which
strong pictorial, medical, and narrative evidence of onset
of overgrowth during childhood (before the age of 8) or
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The study on gigantism and the genetic studies of
patients with pituitary tumors were approved by the Ethics
Committee of the Centre Hospitalier Universitaire de Lie`ge,
Belgium. The studies at the National Institutes of Health
(NIH) Clinical Research Center were approved by the
National Institute of Child Health and Human Develop-
ment Institutional review board (NICHD IRB). Patients or
parents/guardians provided informed consent; children
over the age of 8 years that were seen at the NIH provided
assent. The study was conducted according to the Declara-
tion of Helsinki on the Ethical Principles for Medical
Research Involving Human Subjects.Results
Demographics and genetic diagnosis
Most patients with X-LAG syndrome were sporadic
(13/18; 72.2%). Two families that presented with FIPA had
three and two affected members respectively. The
ethnic backgrounds were diverse: Caucasian European,
South East Asian, Indian subcontinent, First Nations
Canadian, and Latino-Afro-Caribbean backgrounds were all
seen. All patients were the offspring of non-consanguineous
parents. Apart from the familial cases, there were no
histories of growth disorders in any relatives of the affected
patients.Duplications of anapproximately 500 kb regionon
chromosome Xq26.3 (involvingCD40LG,ARHGEF6,RBMX,
and GPR101) were observed for both newly and previously
reported cases (Fig. 1; Trivellin et al. 2014). Studied cases
also shared the previously noted smallest regions of overlap
on a HD-aCGH. Breakpoint analyses revealed that
all non-familial cases were unique rearrangements, which
are likely to be mediated by a fork stalling and template
switching/microhomology-mediated break-induced
replication (FoSTeS/MMBIR) mechanism (Lee et al. 2007,
Hastings et al. 2009, Zhang et al. 2009). Duplications were
visualized by FISH in all cases studied (Fig. 1).Growth and disease characteristics
Patients were generally born at full-term (one sporadic case
was born at 35 weeks) from uncomplicated pregnancies
(Fig. 1 and Table 1). In all but two of the cases, the birth
weight, length, and head circumference were normal. One
female patient, the mother of two familial cases, had a birth
length in excess of the 97th centile, although the birth
weightwasnormal,while another sporadic casewas small forhttp://erc.endocrinology-journals.org q 2015 Society for Endocrinology
DOI: 10.1530/ERC-15-0038 Printed in Great BritainPY ONLYgestational age. Overall, in the X-LAG cohort, the medianage at the onset of rapid growth was 12 months (range: 2–48
months) and, although females had a younger age at the
onset of rapid growth than males, this was not statistically
significant (10.5 versus 14.0 months respectively; PZNS).
The median age at diagnosis was 41 months (range: 14–264
months), and again females were younger than males at
diagnosis (40 versus 56 months respectively; PZNS). At
diagnosis, the median height standard deviation score (SDS)
wasC3.9 (range:C1.9 toC7.6). The median weight SDS was
similarly increasedatdiagnosis: (C4.4; range:C3.0 toC9.3).
The presenting symptoms at diagnosis are shown in
Table 2. Apart from abnormally increased growth in all
patients, the most frequent complaints at presentation were
typically acromegalic-type signs, such as, acral enlargement
(38.9%) and coarsened facial features (33.3%). Some of the
physical features and characteristics are illustrated in Fig. 2.
Interestingly, 7/18 (38.9%) patients had a preceding history
of increased appetite or other food-seeking behavior,
a feature that is not typical of other forms of gigantism.
Four patients (22.2%) had acanthosis nigricans at diagnosis.
At diagnosis, fasting insulin levels were available for
12 patients, of whom six demonstrated fasting hyperinsu-
linemia (including all with acanthosis nigricans). No patient
had diabetes mellitus at diagnosis or during follow-up.
Neurological symptoms such as headache, visual field
defects, ataxia, and seizure occurred in one patient each.Radiological characteristics
MRI findings at diagnosis in a selection of the patient
population are shown in Fig. 3. There was some variability
in the tumor sizes and appearances, from large homogeneous
bean-orpeanut-shapedtumors, tothosewithdiffusepituitary
enlargement suggestive of hyperplasia. All patients had
pituitary abnormalities at diagnosis, of which most appeared
to be a macroadenoma on MRI (14/18), while the remaining
patients had pituitary enlargement without an identifiable
adenoma. The median tumor diameter was 18 mm (range:
10–39 mm). Tumor extension to the optic chiasm was
frequent, occurring in 12 patients, whereas invasion of the
cavernous sinus was present in only two patients at diagnosis.
There were no statistically significant differences in radio-
logical characteristics between males and females.Hormonal measures
GH levels were universally elevated in all patients at
diagnosis. Notably, the random GH levels at diagnosis






















Genetic and growth features of patients with X-LAG syndrome.
(A) Representative chromosome Xq26.3 microduplication from female
sporadic patient S10 onHD-CGH array showing the duplicated region (red) and
details of the breakpoint regions of microhomology leading to the duplication
(below in purple GGCC). (B) FISH results for sporadic patient S1 (male), showing
a duplication of the proximal and distal probes (red/green) in a representative
leukocyte. (C, D) Growth patterns during early life for sporadic patients S5
(female) and S1 (male). Panel C shows the growth of patient S5 that exceeded
the 97 centile for length as early as 6 months of age; she was treated with
cabergoline (DA) and then surgery, after which time the total resection of the
tumor was associated with flattening of her growth curve. She was diagnosed
with panhypopituitarism and diabetes insipidus and required GH supple-
mentation as indicated. Panel D shows the early growth of patient S1,
a sporadic male case, which began between the ages of 9 and 12 months and
continued despite subtotal surgical resection, SSA and DA; the introduction of
pegvisomant (PegV)attheageof6 ledto normalization of IGF-1andadecrease
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(range: six- to 300-fold ULN). Oral glucose tolerance test
(OGTT) data were available for 14 cases; none showed GH
suppression and four showed a paradoxical rise in GHhttp://erc.endocrinology-journals.org q 2015 Society for Endocrinology
DOI: 10.1530/ERC-15-0038 Printed in Great Britainduring the test. IGF1 levels were also elevated at diagnosis
in the 13 cases for which data was available; the median-
fold increase above the ULN was 3.4 (range: 3.1- to 5.2-fold





































S1 M 6/56 [[[ No 4.4 [[[ 27 Sx, SSA, DA, PV PA; GHC/PRLC;
Ki-67: 3%
Yes Yes (7 years) 7 ACTH, TSH, DI




Yes Yes (11 years) 18 TSH, DI
S3 F 18/42 [ No 2.4 [[ 17 Sx, DA, SSA, RTx
(g-knife)
PA; GHC/PRLC No No 7.5 No
S4 F 2/23 [[ ND 5.2 [[ Global
enlargement
DA, SSA Pending surgery No No 3.5 No







S6 F 6/36 [[[ Paradoxical
increase
3.1 [[ 39 DA, Sx, SSA, PV PA; GHC/PRLC;
Ki-67!1%
Yes Yes (5 years) 6 DI




Yes Yes (8 years) 30 TSH
S8 F 11/33 [[[ Paradoxical
increase
3.3 [ 18 DA, Sx, RTx, SSA Eosinophilic
adenoma
No No 8 No
S9 F 3/33 [[ No 3.4 [[ 18; general
enlargement







S10 F 6/43 [[ No 3.3 [[[ 24 DA, Sx, SSA, RTx
(Conv.), PV
PA; GHC/PRLC Yes Yes (4.9
years)
11 No
S11 M 48/67 [[[ No 3.6 [[ 32.5 Sx PA; GHC/PRLC No No 10 No
S12 F 10/48 [ No NA [ 25 Sx, SSA, DA, RTx
(Conv.), PV
PA; GHC/PRLC Yes Yes (adult) 35 ACTH, TSH,
LH
S13 F 48/91 [ Paradoxical
increase
2.6 [ 17; general
enlargement




Yesb No 8 NAb
F1A F 12/31 [[ No NA [[ O10 Sx Eosinophilic
adenoma
Yes Yes (5 years) 45 ACTH, TSH,
GH
F1B M 12/18 [[ No 3.3 [[[ 15 SSA, DA, 3Sx PA plus hyperplasia;
GHC/PRLC
Yes Yes (4 years) 18 ACTH, TSH,
GH








Yes Yes (4 years) 13 ACTH, TSH
F2A M 48/96 [ No NA [ 19 Sx PA; GHC/PRLC Yes Yes (12 years) 23 DI
F2B F Child/264 [ No NA [ O10 Sx PA; GHC/PRLC Yes Yes (adult) 26a ACTH, TSH,
LH
M, male; F, female; ND, not determined; NA, not available; OGTT, Oral glucose tolerance test; ULN, upper limit of the normal range; Sx, surgery; SSA, somatostatin analog; DA, dopamine agonist;
PV, pegvisomant; RTx, radiotherapy; Conv., conventional; PA, pituitary adenoma; DI, diabetes insipidus. For hormonal criteria: [: 2–10! ULN; [[: O10–50! ULN; [[[: O50! ULN.
aPatient died of sepsis aggravated by hypopituitarism.































































































































AUTHOR COTable 2 Signs and symptoms reported in 18 patients withX-LAG syndrome at presentation
Sign/symptom Number of patients (%)
Abnormally increased growth 18 (100)
Acral enlargement 7 (38.9)
Increased appetite 7 (38.9)
Coarsened facial features 6 (33.3)
Acanthosis nigricans 4 (22.2)
Sleep apnea/snoring 3 (16.7)
Excessive perspiration/body odor 3 (16.7)
Widening of interdental spaces 3 (16.7)
Abdominal distension/weight gain 2 (11.1)
Other (pubic hair, prognathism,
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22 :3 35917 patients and were also elevated (median 18-fold over
the ULN (range: 2.0- to 90.8-fold)). No patient exhibited
galactorrhea. Five patients had GHRH levels measured at
diagnosis and, in all cases, these were in the middle of or
just above the ULN. At diagnosis, none of the patients
exhibited hypopituitarism.Therapeutic responses and outcomes
Management of the X-LAG patients was multimodal in the
majority of cases and, in many cases, this was complexA B
Figure 2
Physical changes in representative cases of X-LAG syndrome with Xq26.3
microduplications. (A) Patient S8 is shown at the age of 32 months at which
time her height was O4 SDS (she had been growing at an abnormal rate
since the age of 11 months). Of note are her large hands and feet and facial
features that are moderately coarsened but well proportioned. Panel B
shows widely spaced teeth and a patch of acanthosis nigricans on the
http://erc.endocrinology-journals.org q 2015 Society for Endocrinology
DOI: 10.1530/ERC-15-0038 Printed in Great BritainPY ONLY(Table 1), as illustrated for two cases in Fig. 4. All but oneof the 18 patients underwent neurosurgery, and for the
remaining case, surgery is pending.
Nine patients underwent medical therapy as the initial
modality (dopamine agonist (DA), mostly cabergoline
(Dostinex): nZ7; somatostatin analog (SSA): nZ2) and
none achieved control of either GH or PRL secretion despite
the use of doses normally used in adult patients (SSA
(duration 6–12 months): octreotide, 40 mg/month; lanreo-
tide, autogel 90 mg/month. DA (duration 3–6 months):
0.25 mg 3–5 times weekly). In these patients, surgery was
then employed (1–3 interventions) in all cases (apart from
one patient awaiting surgery) and growth control was
achieved in three cases but at the cost of hypopituitarism.
Further use of SSA (dose: octreotide 30 mg/month; lanreo-
tide 90 mg/month; duration: 6 month–5 years) did not lead
to control in the remaining cases. Radiotherapy (conven-
tional; follow-up: 5–20 years) also did not itself lead to
permanent control of GH hypersecretion. Addition of
pegvisomant (10 mg/day–20 mg four times per week)
permitted control of IGF1 and excessive growth in three
patients who had previously undergone surgery and who
also had developed multiple pituitary axis deficiencies.
Among the nine patients who underwent primary surgical
resection, three had immediate GH/PRL control andC D
left side of her neck. In panel C, patient S9 who began to grow abnormally
at the age of 3 months is pictured shortly after diagnosis (aged 33 months),
when her height was O5 SDS and hands and feet are enlarged. Panel D
shows her facial features, which include a large nose and prominent
mandible and hypertelorism.
Published by Bioscientifica Ltd.
AUTHOR COPY ONLYA C E G
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Figure 3
T1-weighted gadolinium-enhanced MRI images of female patient S9 at
diagnosis (age 2 years 11 months), revealing a large, hypoattenuated
hourglass (‘peanut’)-shaped mass within the sella with expansion of the
diaphragma sella (A and B). Panels C and D show coronal and sagittal
T1-weighted post-contrast images at diagnosis of female patient S6
(age 3 years) showing a large pituitary mass with marked upward and
posterior extension and areas of degenerative changes. Postoperative
images (E and F) from the same patient reveal that the adenoma has been
visibly resected (hormonal and growth control, however, required SSA and
pegvisomant). Panels G and H show coronal and sagittal T1-weighted MRI
images of female patient S10 at diagnosis (aged 3 years), showing a large
homogeneous pituitary mass extending superiorly and posteriorly
(‘bean shaped’); the posterior pituitary is clearly observed as a
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22 :3 360excessive growth was halted. The surgical control was
followed in two cases by the development of panhypopi-
tuitarism and in one by diabetes insipidus (DI). For those
patients in whom growth and GH secretion were not
controlled by their initial surgery, the subsequent manage-
ment was complex. Use of SSA (octreotide 30–
40 mg/month depot, lanreotide 90 mg/month) and DA
(0.25 mg two to seven times per week) postoperatively did
not lead to hormonal or growth control, which was only
achieved with combinations of radiotherapy (conven-
tional or gamma-knife (follow-up!1–10 years)), repeated
surgery, SSA, and finally pegvisomant (10–20 mg/day). SSA
use was associated with a median reduction in GH and IGF1
of 37.5% and 15.2% respectively, whether used as primary
or secondary therapy but in no case was the reduction
sufficient to bring patients under hormonal control. None
of the patients receiving pegvisomant experienced tumor
expansion on therapy, even after more than 5 years of
follow-up. Pasireotide was not available or was not used in
the treatment of any of these patients.
Control of excessive growth was frequently accom-
panied by hypopituitarism (Table 1); one patient hadhttp://erc.endocrinology-journals.org q 2015 Society for Endocrinology
DOI: 10.1530/ERC-15-0038 Printed in Great Britain!1 month of follow-up postoperatively and definitive
growth control/hypopituitarism was difficult to
determine. Four patients remain uncontrolled in terms
of growth. One operated patient is awaiting availability of
SSA and one patient is awaiting surgery but is receiving
100 mg s.c. octreotide daily plus DA; two other children are
receiving 30–40 mg/month octreotide depot and DA, and
have undergone radiotherapy (pegvisomant is not avail-
able in their jurisdiction).Pathological characteristics
Overall, PAs alone were observed in 12 out of 17 patients
that had undergone surgery, PA plus generalized hyper-
plasia in two out of 16 cases, and global hyperplasia alone
in two out of 16 cases. As shown in Table 1, resected tissues
were usually positive on IHC for both GH and PRL alone
and most represented mixed GH–PRL-secreting PAs
(Fig. 5). Proliferation rates (Ki-67) were low (!1%) in
tumors from six cases and were 2–3% in one adenoma.
For six patients, sufficient pituitary tumor tissue was































































































































































































































Time course of the effects of treatment modalities on GH, IGF1, and PRL in
two representative patients with X-LAG syndrome. Panel A shows the
evolution of sporadic patient S1, a male who was diagnosed at the age of
56 months and underwent primary neurosurgical treatment to grossly
resect the visible tumor. This surgical intervention lead to marked decreases
in GH and PRL, but IGF1 remained very high (normal IGF1 range shown as a
grey shaded area). Addition of an SSA (octreotide LAR 30 mg/month) and
later a DA (cabergoline 0.25 mg 5! week) reduced the IGF1 by
approximately 50% from the postoperative level but, as the IGF1 remained
elevated and overgrowth continued, pegvisomant (10 mg/day) was
eventually added and led to a rapid decrease in IGF1, which allowed the
SSA to be withdrawn. In panel B, a female sporadic case S6 first received a
dopamine agonist and later underwent a neurosurgical intervention,
which removed the majority of the visible tumor. The postoperative GH
levels were decreased greatly but remained elevated to an extent that IGF1
secretion was still greatly increased (normal range for IGF1 shown as a grey-
shaded area) and growth continued. Addition of a depot somatostatin
analog (octreotide LAR 30 mg/month) did not control IGF1 alone or in
combination with cabergoline, although IGF1 levels showed approximately
a 40% decrease from levels before SSAs were started. Owing to the lack of
control and continuing somatic overgrowth, pegvisomant was added and
it rapidly brought IGF1 levels and growth under control. As IGF1 levels
dropped to approximately the lower limit of the normal range appropriate
for the age of the patient (5 years), the SSA was withdrawn and the
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22 :3 361to high expression of SSTR2, the main target of somatostatin
analogues such as octreotide and lanreotide, which was
variable but moderate to high in all cases (IRSs 4–10). Despite
the presence of SSTR2 in these cases, none of the six
experienced hormonal or growth control in response to an
SSA, even at doses generally used in adults. Five of the six
tumors stained positively forSSTR5, although at a lower level
than for SSTR2. Four tumors were stained for SSTR1 and
SSTR3, while for two cases only the level of SSTR2 and SSTR5
could be assessed (Fig. 6). One of the four tumors was
negative for SSTR1. SSTR3 is also highly expressed (average
IRS8.8) in theanalyzed tumors.AIPexpressionwaspreserved
at a moderate to high levels among these patients (Fig. 5).Discussion
X-LAG syndrome is a recently described cause of pituitary
gigantism that is due to microduplication of chromosome
Xq26.3 encompassing GPR101; the latter gene is highly
upregulated inpituitary tumors from patients (Trivellin et al.
2014). In this study, we expand the number of described
patients to 18 and focus for the first time, on aspects of the
clinical management of these patients. A number of factors
related to X-LAG syndrome combine to make the clinicalhttp://erc.endocrinology-journals.org q 2015 Society for Endocrinology
DOI: 10.1530/ERC-15-0038 Printed in Great Britainmanagement of this condition challenging. The age of onset
of increased growth in X-LAG syndrome is significantly
younger than that for other pituitary gigantism cases
(Trivellin et al. 2014). In the current study, we confirm that
patients with the Xq26.3 microduplication can exhibit
overgrowth as young as 2–3 months of age, despite being
normally sized newborns. Across the cohort, the onset of
rapid abnormal growth always occurred before the age
of 5 years, and in most patients it occurred before the end of
the first year of life. As this is a newly described disease and,
as infant overgrowth is rare and arguably less prioritized
than failure to thrive, there was a delay in diagnosis in
many cases. Overall, the median delay in diagnosis was
27 months. As a function of this delay (most likely),
unchecked growth of the pituitary hyperplasia–adenoma
led to most patients presenting with macroadenomas
that had expanded to the level of the optic chiasm.
Accompanying the pituitary abnormalities in X-LAG syn-
drome is very marked hypersecretion of GH/IGF1. In one
case the PRL was not elevated and no PRL staining was seen
in the tumor, indicating that PRL hypersecretion does not
always occur in X-LAG syndrome. The action of chronic and
markedly elevated GH and IGF1 on the young patients led to
a phenotype of increased length/height (C3.9 SDS) andPublished by Bioscientifica Ltd.
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Figure 5
Immunohistochemistry of pituitary adenomas from X-LAG syndrome cases.
In case S1 (sporadic male), panel A shows strong GHRHR staining (brown) in
the pituitary adenoma with a C-terminal GHRHR peptide (20! magni-
fication). The tumor was a mixed GH and PRL adenoma and staining of
consecutive slices demonstrated largely different cell populations that
stained for GH (brown; panel B) and PRL (brown; C).
SSTR immunohistochemistry was also performed on tumors from patients
with the Xq26.3 microduplication. AIP staining (brown) shown for three
pituitary tumors from X-LAG syndrome cases (D, E, and F). In all six cases
the tested AIP staining was preserved at moderate to high levels and was
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spectrum of signs and symptoms apart from the increased
growth. Many of these signs echo the clinical features of GH
excess observed in adult acromegaly, including acral
enlargement and facial coarsening. Among the cohort, the
increase in foot size was remarked upon in many cases. In
terms of facial changes, some patients appeared to exhibit
hypertelorism as part of the overall coarsening of the nose
and brow, which would differ from adult acromegaly.
Prognathism itself was rare, but, in three cases, patients
also developed a widening of the interdental spaces (Fig. 2).
Other acromegalic features such as increased perspiration/-
body odor, sleep apnea, and skin thickening were also
reported variably. Unusually, more than a third of patients
had abnormally increased appetite, which has not, to our
knowledge, been reported in association with gigantism
previously. This and the presence of hyperinsulinemia and
acanthosis nigricans indicate that there are metabolic effects
that either stem from or accompany the process of somatic
overgrowth in affected children. The appearance of acrome-
galy signsand symptoms ina youngchild should raisea high
suspicion of an underlying Xq26.3 microduplication.
Treatment of pediatric patients with PAs is complex,
particularly in those – similar to the X-LAG syndromehttp://erc.endocrinology-journals.org q 2015 Society for Endocrinology
DOI: 10.1530/ERC-15-0038 Printed in Great Britaincohort – where the tumor is large and the children are
very young (Jane 2008). A desire for disease control must
be acutely balanced against attempts to maintain normal
function in other anterior pituitary axes while avoiding
DI. The current study highlights for the first time, the
challenges that have been encountered in treating
patients with X-LAG syndrome. SSAs are the mainstay of
medical treatment of GH excess, but in the setting of
X-LAG syndrome their efficacy was poor. No patient
achieved primary or secondary control of their disease or
GH/IGF1 with SSA, even when using adult doses in young
children. We report new data on SSTR levels in PAs from
X-LAG patients, which indicate that the poor SSA
responses to octreotide and lanreotide are not due to low
SSTR2 expression, which was preserved in all cases.
Indeed, in two cases, SSTR2 levels were very high despite
a lack of control of GH or IGF1 with chronic SSA use at
adult-type doses. The genomic abnormality encountered
in X-LAG with tumoral GPR101 overexpression could, in
turn, hypothetically promote growth by concomitantly
down-regulating important signaling elements (e.g.,
ZAC1) linked to SSA effects (Theodoropoulou et al.
2009). A similar but less dramatic scenario has also been
noted to occur with respect to the significantly decreasedPublished by Bioscientifica Ltd.
AUTHOR COPY ONLYS2A B C
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Case SSTR1 SSTR2 SSTR3 SSTR5
S1 0 5 7.5 1
S2 3 10 10 8
S3 2 6 8 4
S6 – 10 – 1
S7 – 4 – 0










SSTR immunohistochemistry was performed on tumors from patients
with the Xq26.3 microduplication and results are shown in the tabulation
(lower panel). Expression of SSTR2 in representative tumor samples of
three X-LAG patients is shown in panels A, B, and C and that of SSTR5 in
panels D, E, and F. Immunoreactive scores for SSTR2 for all three samples
illustrated were high, whereas SSTR5 scores varied from negative to high
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22 :3 363responses to SSA in patients with AIP mutation-associated
acromegaly (Daly et al. 2010, Chahal et al. 2012). However,
staining for AIP, which can be reduced in tumors of
acromegaly patients with poor SSA responses (Kasuki et al.
2012, Jaffrain-Rea et al. 2013), was preserved in X-LAG
patients. Other SSTRs were also preserved to a variable
extent, including SSTR5 and SSTR3, which would indicate
that treatment of patients with X-LAG by targeting
these receptors with a multi-receptor SSA like pasireotide
might be of clinical interest (Cuevas-Ramos & Fleseriu
2014, Eigler et al. 2014). A medical option to achieve
control of IGF1 and physical overgrowth involved the
use of pegvisomant, either alone or in combination with
SSA/DA in a postoperative setting. This option, while
useful, needs to be balanced against the lack of safety data
for pegvisomant in the pediatric setting, although use inhttp://erc.endocrinology-journals.org q 2015 Society for Endocrinology
DOI: 10.1530/ERC-15-0038 Printed in Great Britainpediatric cases has been reported and, in the current
cohort, no evidence of tumor expansion during pegviso-
mant monotherapy was noted (Rix et al. 2005, Mussig
et al. 2007, Goldenberg et al. 2008, Daniel et al. 2013). DA
alone was not sufficient to achieve control of hormonal
hypersecretion in these cases. Neurosurgery was per-
formed or planned in all cases and represents an effective
option but was frequently associated with significant
pituitary dysfunction (including GH deficiency). It should
be noted that in cases where global pituitary hyperplasia is
found, significant hypopituitarism is probably unavoid-
able when pursuing successful surgical resection of
pathological tissue. On the other hand, a very small
residual tumor was capable of maintaining levels of
GH/IGF1 above normal for many years, thereby necessi-
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radiotherapy could also have played a role in preventing
tumor regrowth but the current cohort is probably still
too limited to draw conclusions about the role of radio-
therapy in X-LAG syndrome. Achievement of control of
pediatric overgrowth in the narrow window before this
overgrowth became adult gigantism required recourse to
radical surgery or multimodal combination therapy in the
current cohort.
A unifying feature of the X-LAG syndrome is the
strikingly early age at onset, given that phenotypically the
affected children are born normal and in sporadic cases
come from normal-sized families. The generally normal
prenatal growth in these cases is probably due to the fact
that in utero growth is mediated mainly by IGF2. The early
onset of post-natal overgrowth may be in keeping with the
ontogeny of the maturing hypothalamus and pituitary
during late fetal and early neonatal life. Activity of the
fetal somatotrope axis is high at full term and GH secretion
reaches one of the lifetime peaks on day 1 of postnatal life
(Coutant & Bouhours-Nouet 2012, Veldhuis et al. 2012).
Somatotrope axis regulation in early neonatal life in
animals appears to promote the maintenance of GH
secretory responses to GHRH (less desensitization), while
this effect is accompanied by high levels of GHRH in
infant animals and the induction by GHRH of its own
receptor, GHRHR, only during early life which later wanes




Martin Van Buren Batesa USA M 18
Anna Haining Swana Canada F 18
Ella Kate Ewing USA F 18
Fedor Andreevich Machnow Russia M 18
Edouard Beaupre´b Canada M 18
Joh(a)n Aasenb USA M 18
Albert Johan Kramerb The Netherlands M 18
Robert Pershing Wadlowb USA M 19
Cecil Boling USA M 19
Rigardus Rijnhoutb The Netherlands M 19
Dolores Ann Pullardb USA F 19
Sandra Elaine (Sandy) Allenb USA F 19
Zeng Jinlian China F 19
Yao Defenb China F 19
aSwan and Bates were married and had two pregnancies; one female child wa
10.8 kg and 76 cm in length when born.
bCases for which pituitary pathology was reliably diagnosed/reported.
http://erc.endocrinology-journals.org q 2015 Society for Endocrinology
DOI: 10.1530/ERC-15-0038 Printed in Great BritainPY ONLY1996, Torronteras et al. 1996, 1997, 2012). These factorscould represent a window during which increased GHRH
secretion in a young patient could lead to upregulation of
pituitary GHRHR and the subsequent cellular and hormo-
nal over-activity.
The molecular etiology of the pituitary pathology
remains a matter of debate. As we had demonstrated
previously, of the four candidate coding genes contained
within the common duplicated region, only GPR101 was
upregulated at the level of pituitary tumor tissue,
implicating a role for this GPCR in the pituitary itself
(Trivellin et al. 2014). The finding that the GH/PRL
hypersecretion was accompanied by normal or slightly
elevated GHRH secretion (in the absence of peripheral
sources on imaging scans) indicates that hypothalamic
GHRH dysregulation may also play a part in the
etiology. Results from previous studies of patients with
disease phenotypes that closely resemble X-LAG syn-
drome also indicate an important role for GHRH (Moran
et al. 1990, Zimmerman et al. 1993, Dubuis et al. 1995).
Other factors support this hypothesis. The pathology
observed has similarities to two entities caused by GHRH
hypersecretion. Endocrine malignancies, such as bron-
chial or pancreatic neuroendocrine tumors (NETs), may
rarely secrete GHRH. This scenario leads to unregulated
hyperstimulation of pituitary somatotropes and hyper-
plasia of these cells and concomitant GH/IGF1 excess
(Zatelli et al. 2005, Garby et al. 2012). Such NETs
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where such patients have been mistakenly operated on
for their pituitary pathology before their peripheral
GHRH source was identified, adenomatous changes are
rarely encountered (Borson-Chazot et al. 2012). This is in
contrast to our infant-onset gigantism cohort in which
hyperplasia occurs in a minority of cases and mixed GH-
and prolactin-secreting adenomas predominate. The
second relevant setting is that of GHRH-overexpressing
transgenic mouse models (Hammer et al. 1985). While
these mice have elevated circulating GHRH levels, their
pituitary and growth phenotypes are instructive. Such
mice develop a spectrum of mixed GH- and prolactin-
secreting PAs, with or without accompanying somato-
trope, lactotrope, or mammosomatotrope hyperplasia
(Mayo et al. 1988, Brar et al. 1989, Stefaneanu et al.
1989, Asa et al. 1990, 1992). It has been suggested that
the process behind tumorigenesis in these GHRH
transgenic mice involves an evolution from normal
tissue through hyperplasia to adenoma formation
(Lloyd et al. 1992, Umemura et al. 1995). Another
element implicating GHRH in the etiology of this
infant-onset gigantism syndrome is the widespread
presence of GHRHR in hyperplastic and adenomatous
tissue, as compared with normal pituitary. Such a
presence of GHRHR would seem to be a pre-requisite
for a GHRH-driven disease, particularly as local
pituitary GHRH sources were not found on IHC
(Trivellin et al. 2014).
Most X-LAG syndrome patients were females and
occurred sporadically in genetically normal families,
probably due to new mutations. While transmission was
dominant in all three offspring in the two kindreds with
X-LAG syndrome, currently only transmission from
affected mother to affected son has been observed; the
only unaffected offspring was a clinically and genetically
normal female. There are no cases so far of disease
transmission of affected male to offspring. The preponder-
ance of cases of sporadic females might be due to the
potential negative effect of an Xq26.3 microduplication
on the viability of hemizygous male embryos.
X-LAG syndrome may explain the etiology of some of
the most severe cases of gigantism. As we had described
previously, the medical literature from 1970 (when GH
hypersecretion could be proven by assay) contains reports
of cases with similar clinical features to the X-LAG
syndrome cohort (Trivellin et al. 2014), to which others
can be added (Spence et al. 1972, AvRuskin et al. 1973).
Other earlier cases of infant-onset pituitary gigantism werehttp://erc.endocrinology-journals.org q 2015 Society for Endocrinology
DOI: 10.1530/ERC-15-0038 Printed in Great BritainPY ONLYwell described medically (Todd 1958, de Majo & On˜ativia1960, Hurxthal 1961) and again mirror X-LAG syndrome
closely. Parsing these historical reports and some accom-
panying scientific observations reveals information indi-
cating that many of the tallest patients in history had an
early childhood-onset gigantism phenotype that is highly
reminiscent of X-LAG syndrome. As shown in Table 3,
these cases occurred against a background of a normal
family history and, in some, a pituitary pathology was
demonstrable. At present, the clinical syndrome that most
closely fits the etiology of these cases is X-LAG syndrome.
These cases of extreme gigantism in adults underline the
need for effective therapy to arrest tumor-induced growth
during childhood.
X-LAG syndrome is a new, rare disorder of pituitary
gigantism associated with a phenotype of overgrowth due
to mixed GH- and PRL-secreting PAs/hyperplasia that
usually begins during the first 2 years of life. Early
recognition of these cases may be helped by better clinical
awareness of the characteristic acromegalic symptomatol-
ogy; diagnosis of the underlying Xq26.3 microduplication
is readily achievable using clinical aCGH. Management
of X-LAG syndrome is complicated by the high baseline
levels of GH hypersecretion and therapeutic control of
abnormal growth requires radical surgical resection or
multimodal therapy including pegvisomant. SSA
responses are poor despite the presence of moderate to
high levels of SSTR2 staining. The underlying pathophy-
siology of X-LAG remains to be explained fully, particu-
larly the role of GPR101 in regulating tumor growth by
modulating hypothalamic or pituitary signals.Supplementary data
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